S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
Log in

Pfizer Stock Price, News & Analysis (NYSE:PFE)

$36.34
-0.16 (-0.44 %)
(As of 10/16/2019 04:00 PM ET)
Today's Range
$36.32
Now: $36.34
$36.75
50-Day Range
$34.57
MA: $36.13
$37.28
52-Week Range
$33.97
Now: $36.34
$46.47
Volume13.72 million shs
Average Volume23.74 million shs
Market Capitalization$201.00 billion
P/E Ratio12.11
Dividend Yield3.95%
Beta0.66
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.65 billion
Cash Flow$4.24 per share
Book Value$11.03 per share

Profitability

Net Income$11.15 billion

Miscellaneous

Employees92,400
Outstanding Shares5,531,048,000
Market Cap$201.00 billion
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Tuesday, September 24th. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share on Monday, December 2nd. This represents a $1.44 annualized dividend and a dividend yield of 3.96%. The ex-dividend date of this dividend is Thursday, November 7th. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has approved a stock buyback program on Friday, December 14th 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Monday, July, 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.75 by $0.05. The biopharmaceutical company had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company's quarterly revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.77 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Pfizer.

How can I listen to Pfizer's earnings call?

Pfizer will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $2.76-2.86 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.91. The company issued revenue guidance of $50.5-52.5 billion, compared to the consensus revenue estimate of $53.45 billion.

What price target have analysts set for PFE?

15 brokers have issued 12-month price targets for Pfizer's shares. Their predictions range from $36.00 to $55.00. On average, they expect Pfizer's share price to reach $45.71 in the next year. This suggests a possible upside of 25.8% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 11 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)

Has Pfizer been receiving favorable news coverage?

Headlines about PFE stock have trended positive this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pfizer earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Pfizer.

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 47,830,000 shares, a decrease of 18.3% from the August 30th total of 58,540,000 shares. Based on an average daily volume of 24,780,000 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.9% of the shares of the stock are short sold. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), General Electric (GE), Intel (INTC), Exxon Mobil (XOM), Bank of America (BAC), Merck & Co., Inc. (MRK) and Walt Disney (DIS).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.07%), Hexavest Inc. (0.05%), Gateway Investment Advisers LLC (0.04%), Confluence Investment Management LLC (0.04%), Hamlin Capital Management LLC (0.04%) and Meyer Handelman Co. (0.02%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Artemis Investment Management LLP, Gateway Investment Advisers LLC, Reilly Financial Advisors LLC, State of Alaska Department of Revenue, Hamlin Capital Management LLC, CIBC Private Wealth Group LLC and Hexavest Inc.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Pwmco LLC, Park National Corp OH, Accurate Investment Solutions Inc., Pacer Advisors Inc., Sabal Trust CO, Community Trust & Investment Co. and Fulton Bank N.A.. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.34.

How big of a company is Pfizer?

Pfizer has a market capitalization of $201.00 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com/.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,313 (Vote Outperform)
Underperform Votes:  870 (Vote Underperform)
Total Votes:  2,183
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel